Effects of Pioglitazone on Advanced Glycation End Products Receptor Expression in Hyperglycemic-Induced Aortic Vascular Smooth Muscle Cells in Mice and Its Mechanism

Gao Hongli,Xin Yi,Li Weiping,Shen Xuhua,Di Beibing,Li Hongwei

DOI: https://doi.org/10.3969/j.issn.1007-5410.2018.04.011

2018-01-01

Abstract:Objective To analyze the effect of pioglitazone on the expression of the receptor of advanced glycation end products (RAGE) in hyperglycemic-induced mouse aortic vascular smooth muscle cells (VSMCs) and its mechanism of action. Methods The cultured primary mouse aortic VSMCs were divided into five groups: (1) 5.5 mmol/L D-glucose (normal glucose, NG); (2) 25 mmol/L D-glucose (high glucose, HG); (3) 25 mmol/L D-glucose with 10 μmol/L PIO (HG+ PIO); (4) 25 mmol/L D-glucose with 10 μmol/L PIO and 10 μmol/L GW9662 (HG+ PIO+ GW9662); (5) 25 mmol/L D-glucose with 10 μmol/L GW9662 (HG+ GW9662). Western blot and RT-PCR were used to determine the expression of RAGE and PPAR-γ in VSMCs. Results In cultured VSMCs, high glucose increases the RAGE mRNA (P=0.001) and protein (P=0.002) expression, and PIO downregulated RAGE mRNA (P=0.014) and protein (P=0.006) expression. Blockade of PPAR-γ activity by GW9662 significantly attenuated the inhibitory actions of PIO in cultured VSMCs with high-glucose challenge on RAGE mRNA (P=0.001) and protein (P=0.004). Conclusions PIO has been shown to inhibit high glucose-induced RAGE expression in mouse aortic VSMCs by activating PPAR-γ. Key words: Pioglitazone; Hyperglycemia; Muscle, smooth, vascular; Glycosylation end products, advanced